

8-9-01

A

08/07/01  
J1040 U.S. PTO

Attorney Docket P1219P3  
PATENT

J1040 U.S. PTO  
09/924647  
08/07/01

**CERTIFICATION UNDER 37 CFR 1.10**

EL 599 583 232 US: Express Mail Number

August 7, 2001: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

*Aida Guilan*  
Aida Guilan

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

BOX PATENT APPLICATION  
Assistant Commissioner of Patents  
Washington, D.C. 20231

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Sean Adams,  
Audrey Goddard,  
Austin Gurney,  
Timothy A. Stewart,  
Elizabeth Tomlinson, and  
Xing Xian Yu

Title: **FIBROBLAST GROWTH FACTOR-19 (FGF-19) NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS**

**1. Type of Application**

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. \_\_, filed \_\_, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a continuation-in-part application claiming priority to U.S. application Serial Number 09/767,609, filed January 22, 2001, which is a continuation-in-part of application Serial Number 09/522,342, filed on March 9, 2000, which is a continuation-in-part of application Serial No. 09/284,663, filed on April 15, 1999, which is a continuation of application Serial No. 09/158,342, filed on September 21, 1998, now abandoned, and to International Application Nos. PCT/US98/25190, filed on November 25, 1998, PCT/US99/20594, filed on September 9, 1999, PCT/US99/21090, filed on September 15, 1999, PCT/US99/30999 filed on December 20, 1999 and PCT/US00/04414, filed on February 22, 2000, which applications priority is claimed under 35 USC § 120, and to provisional application Serial No. 60/066,840,

filed November 25, 1997, now abandoned, to which application priority is claimed under 35 USC § 119, the entire disclosure of which is hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional )**

93 pages of specification  
9 pages of claims  
1 page(s) of abstract  
20 sheet(s) of drawings  
☐ formal ☒ informal

### 3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)  
X An executed declaration of the inventor(s) ☐ is enclosed ☒ will follow.

\_\_\_\_ (for Cont./Div. where inventorship is the same or inventor(s) being deleted)  
A copy of the executed declaration/oath filed in the prior application is enclosed  
(37 CFR 1.63(d)).

\_\_\_\_ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

#### 4. Assignment

*(for new and CIP applications)*

  x   An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [x] will follow.

\_\_\_\_ (for cont./div.)  
The prior application is assigned of record to Genentech, Inc.

## 5. Amendments

\_\_\_\_\_ Cancel in this application original claims \_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

\_\_\_\_\_ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

**Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119**

X Amend the specification by inserting before the first line the sentence:

--This is a continuation-in-part application claiming priority to U.S. application Serial Number 09/767,609, filed January 22, 2001, which is a continuation-in-part of application Serial Number 09/522,342, filed on March 9, 2000, which is a continuation-in-part of application Serial No. 09/284,663, filed on April 15, 1999, which is a continuation of application Serial No. 09/158,342, filed on September 21, 1998, now abandoned, and to International Application Nos. PCT/US98/25190, filed on November 25, 1998, PCT/US99/20594, filed on September 9, 1999, PCT/US99/21090, filed on September 15, 1999, PCT/US99/30999 filed on December 20, 1999 and PCT/US00/04414, filed on February 22, 2000, which applications priority is claimed under 35 USC § 120, and to provisional application Serial No. 60/066,840, filed November 25, 1997, now abandoned, to which application priority is claimed under 35 USC § 119, the entire disclosure of which is hereby incorporated by reference....

#### 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$710.00
Total Claims	95	- 20 =	75	X \$18.00	\$1,350.00
Independent Claims	29	- 3 =	26	X \$80.00	\$2,080.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
<b>Filing Fee Calculation</b>					<b>\$4,140.00</b>

#### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$4,140.00. **A duplicate copy of this transmittal is enclosed.**

#### 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

#### 9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☐ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other:

**10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)**

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- \_\_\_\_\_ A petition, fee and/or response has been filed to extend the term in the pending prior application until
- \_\_\_\_\_ A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**


X Address all future communications to:

Attn: Atulya R. Agarwal, Ph.D.

Respectfully submitted,

GENENTECH, INC.

Date: August 7, 2001

By:   
Atulya R. Agarwal, Ph.D.  
Reg. No. 40,887  
Telephone No. (650) 225-4463



09157

PATENT TRADEMARK OFFICE

09157 40887 650